@article{d5fc5e8865c74d238e02865064d03cb6,
title = "Neoadjuvant therapy for melanoma: is it ready for prime time?",
author = "Beth Helmink and Wargo, \{Jennifer A.\}",
note = "Funding Information: JAW reports compensation for speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb, serves as a consultant or advisory board member for Roche–Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Microbiome DX, and also receives research support from GlaxoSmithKline, Roche–Genentech, Bristol-Myers Squibb, and Novartis. BH is supported by the National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant ( P30 CA016672 ). The authors would like to acknowledge all of those who have helped make these efforts possible, including the executive committee and the entire membership of the International Neoadjuvant Melanoma Consortium, academic and industry partners, funding agencies and regulatory bodies, as well as the patients who participated in these trials. ",
year = "2019",
month = jul,
doi = "10.1016/S1470-2045(19)30377-8",
language = "English",
volume = "20",
pages = "892--894",
journal = "The Lancet Oncology",
issn = "1470-2045",
number = "7",
}